Summary & Overview
CPT 81411: Apolipoprotein E (ApoE) Gene Analysis
CPT 81411 covers Apolipoprotein E (ApoE) gene analysis for common variants (for example, *E2, *E3, E4). This molecular genetic test identifies APOE genotypes used in clinical risk assessment and research contexts, and it is commonly performed in laboratory settings. Nationally, APOE testing is notable for its role in evaluating genetic susceptibility in neurodegenerative and vascular conditions, influencing diagnostic evaluation and clinical decision-making in some specialty settings.
Major commercial payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication summarizes coverage considerations and coding context for payers widely used across the United States. Readers will find a concise overview of the clinical purpose of the code, typical billing context, commonly associated claim modifiers, relevant specialty taxonomies, and a list of supporting ICD-10 diagnoses tied to vascular and connective tissue conditions that may prompt testing. The report also situates CPT 81411 alongside related molecular pathology codes to clarify coding hierarchies and laboratory service lines.
This summary is designed to inform billing, coding, and policy teams about the clinical and administrative context of CPT 81411, outline the payer landscape, and provide reference points for related molecular pathology procedures and diagnostic indications. Data not available in the input is noted where applicable.
CPT Code Overview
CPT 81411 is a genetic test for Apolipoprotein E (ApoE) gene analysis, identifying common variants such as *E2, *E3, and *E4. This assay evaluates APOE genotype variants that have clinical relevance in risk assessment and genetic characterization.
Service Type: Genetic Testing
Typical Site of Service: Laboratory (POS 81)
Clinical & Coding Specifications
Clinical Context
A middle-aged patient with a family history of early-onset cardiovascular disease and known aortic pathology presents for genetic evaluation. The patient has a documented aortic aneurysm or dissection or a syndromic connective tissue disorder (e.g., Marfan syndrome or vascular Ehlers-Danlos) and the clinical team orders Apolipoprotein E (ApoE) gene analysis to assess common APOE alleles (*E2, *E3, *E4) that may inform risk stratification for cardiovascular and lipid-related considerations. The typical workflow: test is ordered by a cardiologist, medical geneticist, or clinical genetic counselor; specimen (blood or saliva) is collected and sent to the laboratory (POS 81); the laboratory performs genotyping; a result report is generated and delivered to the ordering clinician; the professional component may involve interpretation by a board-certified clinical geneticist or molecular pathologist and documented in the medical record.
Coding Specifications
Modifier 26 - Professional Component
- Use when billing only the professional interpretation component of the genetic test performed by a qualified physician or other allowed professional.
Modifier 59 - Distinct Procedural Service
-
Use when the ApoE gene analysis is a distinct service separate from other procedures performed on the same day for the same patient; applies when documentation supports separate and independent services.
-
Provider Taxonomies:
| Taxonomy Code |
|---|